Navidea Biopharmaceuticals, Inc.
NAVB · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | -8,102.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -524,539.7% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -570,922.8% |
| EPS Diluted | -0.023 | 0.12 | -0.045 | -0.11 |
| % Growth | -118.9% | 365.5% | 58.9% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |